NEW YORK – Twist Bioscience and Takeda Pharmaceutical Company said on Wednesday that they have agreed to partner to develop new antibodies needed for oncology, rare disease, neuroscience, and gastroenterology therapies.
Under the terms of the agreement, Twist Bio will give Takeda access to its proprietary phage display libraries to aid the pharmaceutical company in the discovery, validation, and optimization of antibodies needed for the development of new biologics. Twist business division Twist Biopharma will grant Takeda a license to its Library of Libraries, a panel of synthetic antibody phage display libraries derived from sequences that exist in the human body. Takeda will pay Twist annual technology licensing fees, as well as milestones and royalties for all compounds discovered from the Twist libraries.
"Twist's unique ability to generate robust, diverse, and cutting-edge libraries through its proprietary silicon platform together with our deep insight into therapeutic drug discovery and development will help us expand a growing pipeline of targeted biologic candidates," Robert Mabry, Takeda's head of global biologics research, said in a statement.